Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
- 10 September 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (26) , 6339-6344
Abstract
Molecular diagnostic tools and novel therapeutics now offer the potential for accurate prognostic and personalized treatment road maps for patients with multiple myeloma (MM). We will review the evidence and provide specific recommendations for routine clinical molecular genetic testing and use of such information to guide therapeutic decision making. In particular, the negative prognostic impact of specific IgH translocations such as the t(4;14), t(14;16), chromosome 13 deletion by conventional cytogenetics and loss of 17p13 by interphase fluorescence in situ hybridization are now established. Preliminary gene expression profiling studies have also demonstrated that individual genes (CSK1-B) or groups of genes can define prognosis with greater accuracy than conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysiology, therapeutics, and future targets of myeloma. Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification.Keywords
This publication has 48 references indexed in Scilit:
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple MyelomaLeukemia & Lymphoma, 2004
- Multiple MyelomaHematology-American Society Hematology Education Program, 2004
- Treatment of multiple myelomaBlood, 2004
- Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid casesGenes, Chromosomes and Cancer, 2003
- Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the diseaseBlood, 2003
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arraysOncogene, 2002
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosisHuman Mutation, 2001